Sugi Predict

Sugi Predict / Compounds / SCHEMBL8665512

SCHEMBL8665512

SCHEMBL8665512

O=C1c2cccc([N+](=O)[O-])c2C(=O)C1(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 9/20 1.00
▸ CA2 P00918 9/20 1.00
▸ CA7 P43166 9/20 1.00
▸ CA9 Q16790 9/20 1.00
▸ S100A4 P26447 2/20 0.58
▸ PTPRC P08575 1/20 0.53
▸ RECQL P46063 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ MCL1 Q07820 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ CASP1 P29466 1/20 0.48
▸ BACE1 P56817 1/20 0.48
▸ EHMT2 Q96KQ7 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ GPR35 Q9HC97 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30260486 1.00 CA1 (1.00) CA1CA2CA7CA9S100A4
SCHEMBL28285608 0.74 CA1 (0.67) CA1CA2CA7CA9PTPRC
SCHEMBL2347136 0.74 S100A4 (0.84) CA1CA2CA7CA9S100A4
SCHEMBL28651375 0.74 S100A4 (0.92) CA1CA2CA7CA9S100A4
SCHEMBL9257330 0.74 S100A4 (0.77) CA1CA2CA7CA9S100A4
SCHEMBL2599501 0.74 S100A4 (1.00) CA1CA2CA7CA9S100A4
Silver SCHEMBL29163240 0.74 CA1 (0.74) CA1CA2CA7CA9RECQL
SCHEMBL7625099 0.73 S100A4 (0.63) CA1CA2CA7CA9S100A4
SCHEMBL30408893 0.73 S100A4 (0.63) CA1CA2CA7CA9S100A4
SCHEMBL3039191 0.72 TDP1 (0.67) CA1CA2CA7CA9S100A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3597184-B1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES KOREA RES INST CHEMICAL TECH (KR) 2026-03-04 — — EP disclosed
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 — — US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 — — US disclosed
US-20250090491-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2025-03-20 — — US disclosed
US-12083092-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2024-09-10 — — US disclosed
EP-4360710-A2 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2024-05-01 — — EP disclosed
EP-3611158-B1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT KOREA RES INST CHEMICAL TECH (KR) 2023-12-20 — — EP disclosed
CN-115916763-A Antivirals 1, 3-dioxoindene compounds 诺华股份有限公司 2023-04-04 — — CN disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 — — CN disclosed
EP-4139290-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS Novartis AG (CH) 2023-03-01 — — EP disclosed
US-9464067-B2 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2016-10-11 — — US disclosed
US-20160272564-A1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2016-09-22 — — US disclosed
US-9346749-B2 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2016-05-24 — — US disclosed
US-20140121187-A1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2014-05-01 — — US disclosed
EP-2722322-A2 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2014-04-23 — — EP disclosed
EP-2722042-A2 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES Korea Research Institute of Chemical Technology (KR) 2014-04-23 — — EP disclosed
EP-0646574-B1 Ketonic indane derivatives, their preparation and therapeutic application thereof INNOTHERA LAB SA (FR) 1998-12-09 — — EP disclosed
US-5591848-A Spiroconjugated charge-transfer dyes for optical applications THE PENN STATE RESEARCH FOUNDATION (US) 1997-01-07 — — US disclosed
EP-0646574-A1 Ketonic indane derivatives, their preparation and therapeutic application thereof LABORATOIRE INNOTHERA Société Anonyme (FR) 1995-04-05 — — EP disclosed
EP-0646579-A1 Ketonic indane derivatives and heterocyclic analysis and their use in therapy LABORATOIRE INNOTHERA Société Anonyme (FR) 1995-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272564-A1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT RNASE1, PEAK1, PARK7 CA1 1538/4885CA2 2183/4885CA7 1137/4885
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 CA1 4599/4885CA2 3508/4885CA7 2016/4885
US-20250090491-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, MAVS CA1 4762/4885CA2 4124/4885CA7 2637/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 CA1 4599/4885CA2 3508/4885CA7 2016/4885
US-12083092-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, MAVS CA1 4762/4885CA2 4124/4885CA7 2637/4885
US-20140121187-A1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT RNASE1, PARK7, PEAK1 CA1 1279/4885CA2 2698/4885CA7 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.